While epilepsy-related head trauma was common, 9 of 10 patients displayed no evidence of CTE.
The FDA has cleared the Embrace smart watch for managing epilepsy.
Add-on cannabidiol is associated with reduced monthy drop seizure frequency in patients with Lennox-Gastaut sydrome associated drop seizures.
Clinicians should evaluate their patients, especially patients with focal epilepsy, for mood disorders.
Women receiving topiramate for epilepsy were exposed to high cumulative doses, increasing the risk for oral clefts in offspring.
Patients with tough-to-treat seizures may require nonpharmacologic treatment such as resective surgery.
Over one-third of patients with newly diagnosed epilepsy do not respond to antiepileptic drug treatment.
Vitamin B6 was found to effectively treat the behavioral adverse effects seen with levetiracetam.
Research has found that gabapentin and pregabalin induced myoclonus is often seen but is rarely documented.
Children who are exposed to AEDs in utero may have a reduced risk of autistic traits.
Lamotrigine and levetiracetam are just as effective as other AEDs, and are better tolerated as well.
The FDA has accepted for filing with Priority Review the NDA for cannabidiol as seizure treatment.
The findings emphasize the importance of seizure control before pregnancy in women with epilepsy.
Stimulation of the other brain structures resulted in no significant blood pressure changes among the studied participants.
In patients with severe refractory focal epilepsy, add-on treatment with perampanel may be beneficial.
The findings further the utility of cerebral oximetry as a neurological assessment tool.
ZX008 has received Orphan Drug designation and Fast Track designation by the FDA for the treatment of Dravet syndrome.
Researchers from the University of Colorado reported on whether or not maternal antibiotic use during labor increased the risk of seizure for the neonate.
Treatment with enzalutamide for metastatic castration-resistant prostate cancer patients is not linked with increased seizure incidence.
Vigabatrin may be an effective option for patients with seizures due to tuberous sclerosis who do not respond to other anti-seizure treatments.
A study assessed longitudinal behavior in pediatric patients with childhood absence epilepsy and made recommendations regarding initial preferred monotherapy.
Investigators believe this is the largest study on the association between multiple sclerosis and epilepsy.
Duration of Ictal Hypoxemia is Associated With Potentially High-Risk Cardiac Arrhythmias in EpilepsyDecember 06, 2017
Duration of ictal/postictal hypoxemia may be associated with potentially high-risk cardiac arrhythmias during FBTCSs/GTCSs.
Clobazam is currently FDA-approved for the treatment of seizures associated with Lennox-Gastaut syndrome in children 2 years and older.
The diagnostic tool may be especially useful in cases of nonlesional mesial temporal lobe epilepsy.
Patients with refractory epilepsy who fail to benefit from 2 or more AEDs should be referred to alternative therapies.
Patients who died from suspected SUDEP had extensive damage to areas of the mid-brain and brainstem that control autonomic function.
Continuous Infusion in Refractory Status Epilepticus Linked to Increased Mortality, Longer Hospital StayDecember 03, 2017
Researchers compared outcomes between patients treated with continuous infusion or repeated doses of nonbenzodiazepine anti-seizure medication.
Cannabidiol Effective for Reducing Drop Seizures in Lennox-Gastaut Syndrome Regardless of Clobazam UseDecember 03, 2017
The study was a post-hoc analysis of responders who were on or off concomitant clobazam.
Patients undergoing treatment for ischemic stroke are at greater risk for seizure development.
Neurology Advisor Articles
- FDA Approves Blood Test to Assess Concussion
- Shortcomings in ALS Research: Strategies for Improvement
- Comparing Reference Points for Deep Brain Stimulation Location in Parkinson Disease
- Solanezumab Every 4 Weeks Does Not Significantly Affect Cognitive Decline in Alzheimer Disease
- FDA Approves Clinical Decision Support Tool for Stroke
- Arimoclomol Shows Promise for Treating Rapidly Progressive SOD1 ALS
- CNS Abnormalities Common in Erdheim-Chester Disease
- Trial of Verubecestat for Prodromal Alzheimer Disease Discontinued
- Ischemic Stroke, Myocardial Infarction Both Tied to Lipoproteins, Lipids
- Tamsulosin Associated With Dementia Risk in Older Patients With BPH